Trends and predictors of radiation exposure in percutaneous coronary intervention: the PROTECTION VIII study.


Journal

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
ISSN: 1969-6213
Titre abrégé: EuroIntervention
Pays: France
ID NLM: 101251040

Informations de publication

Date de publication:
22 Jul 2022
Historique:
pubmed: 26 1 2022
medline: 26 7 2022
entrez: 25 1 2022
Statut: epublish

Résumé

Percutaneous coronary intervention (PCI) is indispensable in cardiology; however, exposure to potentially harmful ionising radiation remains a concern. This study was designed to assess the PCI-related radiation dose over the last decade and to identify predictors of increased dose exposure. The PROcedural radiaTion dose Exposure in percutaneous Coronary intervenTION (PROTECTION VIII) study included all PCIs reported to a German quality assurance programme between 2008 and 2018. Dose area product (DAP) and radiation time were analysed. Effective dose (ED) was estimated (ED=DAP*k; conversion coefficient k=0.0022 mSv/cGy*cm We enrolled 3,704,986 patients undergoing PCI (median age 70 years, 30% female). Indications were chronic coronary syndrome (37.5%), unstable angina pectoris and non-ST-segment elevation myocardial infarction (non-STEMI; 33.2%) and STEMI (18.5%). Median DAP was 4,203 (interquartile range [IQR] 2,313-7,300) cGy*cm, ED was 9.2 mSv and median radiation time was 9.2 (IQR 5.8-15.0) min. Within the 10-year period, radiation exposure was reduced by 36% (p<0.001) and resulted in a median DAP of 3,070 cGy*cm (ED 6.8 mSv) in 2018. A significant 5.3-fold variability of median DAP was observed between catheterisation laboratories (p<0.001). We identified patient-related (gender, coronary artery bypass graft surgery, heart failure) and procedure-related (coronary occlusion PCI, ostial lesion PCI, left main PCI, multivessel PCI) predictors of increased radiation dose (all p<0.001). This radiation dose survey demonstrates a considerable reduction of PCI radiation exposure during the last decade. However, large variability between catheterisation laboratories underlines the need for further radiation dose reduction.

Sections du résumé

BACKGROUND BACKGROUND
Percutaneous coronary intervention (PCI) is indispensable in cardiology; however, exposure to potentially harmful ionising radiation remains a concern.
AIMS OBJECTIVE
This study was designed to assess the PCI-related radiation dose over the last decade and to identify predictors of increased dose exposure.
METHODS METHODS
The PROcedural radiaTion dose Exposure in percutaneous Coronary intervenTION (PROTECTION VIII) study included all PCIs reported to a German quality assurance programme between 2008 and 2018. Dose area product (DAP) and radiation time were analysed. Effective dose (ED) was estimated (ED=DAP*k; conversion coefficient k=0.0022 mSv/cGy*cm
RESULTS RESULTS
We enrolled 3,704,986 patients undergoing PCI (median age 70 years, 30% female). Indications were chronic coronary syndrome (37.5%), unstable angina pectoris and non-ST-segment elevation myocardial infarction (non-STEMI; 33.2%) and STEMI (18.5%). Median DAP was 4,203 (interquartile range [IQR] 2,313-7,300) cGy*cm, ED was 9.2 mSv and median radiation time was 9.2 (IQR 5.8-15.0) min. Within the 10-year period, radiation exposure was reduced by 36% (p<0.001) and resulted in a median DAP of 3,070 cGy*cm (ED 6.8 mSv) in 2018. A significant 5.3-fold variability of median DAP was observed between catheterisation laboratories (p<0.001). We identified patient-related (gender, coronary artery bypass graft surgery, heart failure) and procedure-related (coronary occlusion PCI, ostial lesion PCI, left main PCI, multivessel PCI) predictors of increased radiation dose (all p<0.001).
CONCLUSIONS CONCLUSIONS
This radiation dose survey demonstrates a considerable reduction of PCI radiation exposure during the last decade. However, large variability between catheterisation laboratories underlines the need for further radiation dose reduction.

Identifiants

pubmed: 35076020
pii: EIJ-D-21-00856
doi: 10.4244/EIJ-D-21-00856
pmc: PMC9912963
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e324-e332

Références

Am J Cardiol. 2013 May 1;111(9):1368-72
pubmed: 23419190
JACC Cardiovasc Interv. 2021 Sep 13;14(17):1958-1960
pubmed: 34503751
JACC Cardiovasc Interv. 2014 May;7(5):550-7
pubmed: 24746655
Int J Cardiovasc Imaging. 2018 Aug;34(8):1185-1192
pubmed: 29572584
Am J Cardiol. 2016 Aug 1;118(3):353-6
pubmed: 27344273
J Am Coll Cardiol. 2015 Jun 9;65(22):2388-400
pubmed: 26046732
J Am Coll Cardiol. 2004 Oct 6;44(7):1420-8
pubmed: 15464322
Phys Med Biol. 1992 Nov;37(11):2117-26
pubmed: 1438564
Heart. 2005 Dec;91(12):1615-20
pubmed: 16287755
Am J Cardiol. 2017 Sep 15;120(6):927-930
pubmed: 28739037
Tex Heart Inst J. 2019 Jun 1;46(3):167-171
pubmed: 31708696
Catheter Cardiovasc Interv. 2015 Nov;86(5):927-32
pubmed: 26010374
Eur Heart J. 2016 Jan 14;37(3):267-315
pubmed: 26320110
J Am Coll Cardiol. 2014 Nov 4;64(18):1929-49
pubmed: 25077860
Biomed Res Int. 2013;2013:976962
pubmed: 24027768
JACC Cardiovasc Interv. 2020 Apr 13;13(7):846-856
pubmed: 32273096
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
Catheter Cardiovasc Interv. 2016 Dec;88(7):1046-1055
pubmed: 26707858
J Interv Cardiol. 2018 Dec;31(6):807-814
pubmed: 30168209
Cardiology. 2012;123(3):168-71
pubmed: 23128776
J Am Coll Cardiol. 2004 Dec 7;44(11):2259-82
pubmed: 15582335
Circulation. 2014 Dec 23;130(25):2354-94
pubmed: 25249586
Eur Heart J. 2020 Jan 14;41(3):407-477
pubmed: 31504439

Auteurs

Thomas J Stocker (TJ)

Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Munich, Germany.
DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.
European Alliance for Medical Radiation Protection Research (EURAMED): The EURAMED rocc-n-roll project (www.euramed.eu).

Mohamed Abdel-Wahab (M)

Heart Center Leipzig at University of Leipzig, Leipzig, Germany.

Helge Möllmann (H)

Department of Internal Medicine, Medizinische Klinik 1, St. Johannes-Hospital, Dortmund, Germany.

Simon Deseive (S)

Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Munich, Germany.
DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.

Steffen Massberg (S)

Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Munich, Germany.
DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.

Jörg Hausleiter (J)

Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-Universität, Munich, Germany.
DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.
European Alliance for Medical Radiation Protection Research (EURAMED): The EURAMED rocc-n-roll project (www.euramed.eu).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH